Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma

Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility

(2019) Marc Humbert et al.   RESPIRATORY MEDICINE

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

(2018) Bradley E. Chipps et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study

(2018) Marc Humbert et al.   EUROPEAN RESPIRATORY JOURNAL

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

(2017) Geoffrey L Chupp et al.   Lancet Respiratory Medicine

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment

(2016) A. Magnan et al.   ALLERGY

Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma

(2016) Trung N. Tran et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Reductions in eosinophil biomarkers by benralizumab in patients with asthma

(2016) Tuyet-Hang Pham et al.   RESPIRATORY MEDICINE

Asthma phenotypes and IgE responses

(2015) Antoine Froidure et al.   EUROPEAN RESPIRATORY JOURNAL

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploring the Effects of Omalizumab in Allergic Asthma

(2013) Nicola A. Hanania et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy

(2013) Nicola A. Hanania et al.   ANNALS OF INTERNAL MEDICINE

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

(2013) K. F. Chung et al.   EUROPEAN RESPIRATORY JOURNAL

Severe asthma: from characteristics to phenotypes to endotypes

(2012) S. Wenzel   CLINICAL AND EXPERIMENTAL ALLERGY

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

(2010) Roland Kolbeck et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY